CD8A and neoplasm: Additionally, TCF-1+TOX+CD8+ T cells(TCF-1: T-cell Factor 1) and tumor-specific memory T cells derived from TdLNs have been identified as primary responders to PD-1/PD-L1 blockade therapy, highlighting their pivotal role in enhancing immunotherapy efficacy (43, 44) (Figure 1).